Tag Archives: Novartis

Novartis’ slow-rolling Kymriah wins coverage in Japan at $305K: report

After snagging the first Japanese CAR-T approval in March, Novartis has won the go-ahead to sell its groundbreaking med, Kymriah, under the country’s national insurance system. And that gives the brand a chance to boost lagging sales. The Central Social Insurance Medical Council of Japan’s Ministry of Health, Labor and Welfare has approved coverage of… Read More »

Novartis puts AI on the job to help reps say the right things to the right doctors

SAN FRANCISCO—Artificial intelligence is a big buzzword in R&D right now, but at Novartis, it’s hard at work in the sales department, too. Amid far more meetings with digital companies at the J.P. Morgan Healthcare Conference this year, Novartis’ pharma CEO Paul Hudson said he expects 2019 to be the “beginning of the tech disruption” for… Read More »

ASH: Gilead, Novartis tout long-term data for CAR-T slow starters Yescarta, Kymriah

SAN DIEGO—Gilead and Novartis are working to ramp up launches of their slow-starting CAR-T drugs, and both companies are hoping longer-term follow-up data will help do the trick. Sunday at the American Society of Hematology (ASH) annual meeting, Gilead’s Kite unit rolled out two-year data from the Zuma-1 study that won Yescarta its October 2017 approval… Read More »